GlycoVaxyn Raises $22 Million
GlycoVaxyn, a Swiss developer of conjugated vaccines, has raised CHF 25 million ($22m) in Series B funding. Edmond de Rothschild Investment Partners led the round, and was joined by return backers Index Ventures and Sofinnova Partners.
5 March 2009•2 mins read
